








Mucin 16 and kallikrein 13 as potential
prognostic factors in colon cancer:
Results of an oncological 92-multiplex
immunoassay
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Abstract
Colon cancer represents one of the most common cancers in the world. Despite improved treatment, mortality remains
high. In order to improve the assessment of prognosis for colon cancer patients, identifying new prognostic markers
remains necessary. We analyzed preoperative serum samples from 148 colon cancer patients surgically treated at
Helsinki University Hospital from 1998 through 2002 using a multiplex proximity extension assay (Oncology II panel,
Olink Bioscience, Uppsala, Sweden), a panel constituting 92 immunological and oncological markers. We performed uni-
variate and multivariate analyses on these patients and calculated the disease-specific survival among patients using the
log-rank test for Kaplan–Meier estimates. In the univariate survival analysis of 92 biomarkers, 26 resulted in p \ 0.1.
Among these, eight biomarkers emerged as statistically significant (p \ 0.05). Patients with low levels of kallikrein 13 had
a poor prognosis. Moreover, patients with high levels of amphiregulin, carcinoembryonic antigen-related adhesion mole-
cule 5, interleukin 6, mucin 16, syndecan 1, transforming growth factor alpha, and vimentin also had a poor prognosis. In
the multivariate analysis, kallikrein 13 and mucin 16 emerged as independent prognostic markers. The role of kallikrein
13, a member of the serine protease kallikrein biomarker family, in tumorigenesis remains unclear. Mucin 16 is also
known as carbohydrate antigen 125, a well-known ovarian cancer biomarker. Patients with low levels of kallikrein 13
(hazard ratio: 0.36; 95% confidence interval: 0.14–0.92; p = 0.033) and high levels of mucin 16 (hazard ratio: 3.15; 95%
confidence interval: 1.68–5.93; p \ 0.005) had a poor prognosis. Mucin 16 and kallikrein 13 represent independent prog-
nostic markers for colon cancer. Furthermore, the clinical utility of mucin 16 and kallikrein 13 serum tests warrants addi-
tional investigation.
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Introduction
Colorectal cancer (CRC), the third most common can-
cer with the second highest mortality rate in the world,1
consists of colon cancer (CC) and rectal cancer. These
divisions result from differences in their pathophysiol-
ogy and histology. In the Nordic countries, CRC has a
5-year overall survival of 65%.2
Serum carcinoembryonic antigen (CEA) is routinely
used in patient follow-up.3 Other tumor markers, such
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as IL-8, prolactin, and carbohydrate antigen 19-9
(CA19-9), are comparable to CEA, but fall short in
terms of adding value to prognostics.4,5 However, an
elevated CA19-9 level in CRC patients with lymph
node invasion serves as an independent prognostic
marker and may carry further prognostic value along-
side an elevated CEA level.5,6
We continue to need new and accurate blood-based
biomarkers. Proximity ligation assay (PLA) and prox-
imity extension assay (PEA) represent homogeneous
immunoassays with demonstrated sensitivity and speci-
ficity.7,8 In PEA, upon binding to the target protein,
antibodies linked to oligonucleotides are pair-bound
and quantified using real-time quantitative polymerase
chain reaction (PCR).8 A promising prognostic algo-
rithm for CRC patients emerged in a recent study using
the Proseek Multiplex Oncology I v2963 96 immunoas-
say (Olink Bioscience, Uppsala, Sweden).9 Furthermore,
by means of Olink technology, metabolic syndrome
patients with low levels of hepatocyte growth factor and
endothelial cell-specific molecule-1 carried an increased
risk of developing CRC.10
Thus, in this study, we aimed to screen for biomar-
kers that can be used to evaluate CC prognosis using
the Proseek Multiplex Oncology II panel.
Patients and methods
Patients
The cohort constituted 148 consecutive CC patients
operated on at Helsinki University Hospital between
1998 and 2002. The mean age of the patients reached
67.8 (range: 31.7–92.6), and 85 (57%) were women.
Comorbidities of the patients were recorded and corre-
sponded to that of their age group (Supplementary
Table 1). None of the patients received neoadjuvant
chemotherapy. According to the Dukes stage classifica-
tion, 21 patients had stage A disease, 54 had stage B, 51
had stage C, and 22 had stage D disease. For the sub-
group analysis, we combined stages A and B (n=75
patients) and C and D (n=73 patients; Table 1). In
total, tumor histology for 131 (89%) patients indicated
non-mucinous adenocarcinoma, while for 16 (11%)
patients, it indicated mucinous.
Serum samples
Serum samples were drawn after one night’s fasting
according to the hospital’s routine procedures, a med-
ian of 1 day prior to surgery (range: 27 days) alongside
other laboratory tests. Without delay, samples were
transported to the laboratory, centrifugated, aliquoted,
and stored at 280C until assayed.
Protein profiling
We determined 92 oncology-associated protein biomarker
levels involved in tumorigenesis using the Proseek
Multiplex Oncology II immunoassay panel (Olink
Bioscience; Table 2, Supplementary Table 2). The selected
biomarkers mirror different biological mechanisms, such
as angiogenesis, cell signaling, cell cycle control, and
inflammation. Patient information was blinded to the
Olink Bioscience personnel who processed the samples
according to their manual, checked the quality of the out-
put data, and normalized the measurement results.
In PEA, 1mL of the sample was incubated with
oligonucleotide-marked antibodies pair-bound to the
fitting targets.8 In brief, pairs of oligonucleotide-labeled
antibody probes bind to their targeted protein, and if
the two probes are brought in close proximity, the oli-
gonucleotides will hybridize in a pair-wise manner. The
addition of a DNA polymerase leads to a proximity-
dependent DNA polymerization event, generating a
unique PCR target sequence. The resulting DNA
sequence is subsequently detected and quantified using
a microfluidic real-time PCR instrument (Biomark
HD, Fluidigm Corporation, San Fransisco, USA).
Data normalization of protein profiling
The concentrations of the biomarkers were determined
as the relative quantification using the normalized pro-
tein expression (NPX). Normalization was performed
by subtracting extension control Ct values and inter-
plate control Ct values from the analyte Ct values. A
run time specific correction factor was used to correct
for normal background level. NPX is an arbitrary unit
on a log2 scale, inverted to that of the raw




















Table 2. List of biomarkers analyzed using the proximity extension assay with the Olink Oncology II panel.
Biomarker Median (pg/mL) IQR (pg/mL) HR 95% CI p valuea
5’-NT 9.26 8.74–9.77 1.25 0.87–1.81 0.518
ABL1 3.19 2.54–3.88 1.15 0.84–1.58 0.728
ADAM 8 3.95 3.73–4.26 1.95 0.94–4.06 0.323
ADAM-TS 15 3.40 3.01–3.77 2.19 1.18–4.04 0.095
ANXA1 1.28 0.95–1.67 1.31 0.91–1.89 0.413
AREG 2.36 1.92–3.00 1.89 1.38–2.58 0.003
CAIX 2.53 2.06–3.40 0.94 0.69–1.26 0.935
CD160 4.67 4.34–5.19 1.08 0.69–1.70 0.935
CD207 2.13 1.86–2.49 1.05 0.55–2.01 0.967
CD27 7.73 7.41–8.13 1.37 0.79–2.38 0.543
CD48 6.36 6.09–6.66 1.45 0.70–3.00 0.628
CD70 3.36 3.10–3.81 1.13 0.68–1.88 0.935
CEACAM1 7.09 6.99–7.22 1.50 0.23–9.81 0.935
CEACAM5 2.50 1.82–3.63 1.32 1.13–1.54 0.011
CPE 3.16 2.93–3.52 1.14 0.53–2.46 0.935
CRNN 4.82 4.21–5.40 1.05 0.74–1.48 0.957
CTSV 2.49 2.07–2.86 0.59 0.36–0.98 0.202
CXCL13 8.06 7.58–8.66 1.32 0.96–1.81 0.343
CXL17 4.32 3.95–4.81 1.01 0.46–1.54 0.983
CYR61 4.20 3.86–4.57 1.56 0.96–2.54 0.323
DKN1A 3.83 2.91–4.68 0.98 0.78–1.22 0.967
DLL1 8.97 8.72–9.29 1.83 0.90–3.72 0.347
EGF 7.87 7.05–8.68 1.06 0.84–1.34 0.935
EPHA2 1.43 1.15–1.83 1.93 1.16–3.22 0.095
ERBB2 6.57 6.40–6.79 1.14 0.40–3.26 0.961
ERBB3 7.35 7.20–7.53 0.91 0.31–2.67 0.967
ERBB4 4.47 4.26–4.70 1.18 0.48–2.88 0.935
ESM-1 8.81 8.46–9.13 1.53 0.82–2.85 0.442
FADD 2.20 1.48–3.10 1.08 0.83–1.40 0.897
FASLG 8.27 7.93–8.57 0.92 0.50–1.71 0.957
FCRLB 1.48 1.06–2.12 1.33 0.96–1.84 0.343
FGF-BP1 4.61 4.39–4.87 0.80 0.43–1.51 0.826
FR-alpha 6.39 6.09–6.67 1.16 0.66–2.04 0.931
FR-gamma 6.63 6.39–6.98 1.05 0.93–1.19 0.750
FURIN 3.59 3.32–3.84 2.78 1.27–6.09 0.095
Gal-1 5.81 5.64–5.98 2.17 0.63–7.49 0.518
GPC1 3.78 3.54–4.03 1.00 0.47–2.14 0.996
GPNMB 5.98 5.83–6.14 1.52 0.39–5.89 0.897
GZMB 2.55 2.14–2.90 0.99 0.65–1.51 0.983
GZMH 3.64 3.01–4.20 0.97 0.66–1.41 0.967
HGF 6.19 5.90–6.61 1.67 1.09–2.56 0.133
hK11 4.96 4.68–5.37 1.54 0.87–2.73 0.410
hK14 5.91 5.54–6.22 0.89 0.51–1.55 0.935
hK8 5.71 5.41–6.04 0.50 0.26–0.97 0.202
ICOSLG 3.60 3.38–3.75 1.26 0.45–3.57 0.935
IFN-gamma-R1 3.54 3.33–3.86 1.88 0.89–3.99 0.347
IGF1R 2.81 2.63–3.07 2.13 1.04–4.34 0.202
IL6 2.45 1.75–3.43 1.50 1.19–1.88 0.011
ITGAV 3.09 2.91–3.32 0.51 0.21–1.26 0.410
ITGB5 8.25 8.02–8.45 1.27 0.56–2.87 0.897
KLK13 3.31 2.82–3.76 0.48 0.29–0.79 0.048
LY9 5.00 4.73–5.37 1.49 0.77–2.90 0.518
LYN 2.76 1.99–3.22 1.02 0.72–1.44 0.978
LYPD3 3.39 3.13–3.67 1.03 0.48–2.22 0.979
MAD homolog 5 2.94 2.80–3.04 0.97 0.20–4.62 0.983
MetAP 2 4.04 3.45–4.67 1.17 0.80–1.71 0.750
MIA 9.72 9.60–9.96 0.90 0.30–2.65 0.967
MIC-A/B 3.64 2.71–4.20 1.03 0.89–1.19 0.935
MK 6.47 6.11–6.94 1.31 0.91–1.89 0.410
MSLN 1.84 1.38–2.37 0.96 0.63–1.47 0.967
MUC-16 2.92b 2.33–3.65b 1.91 1.45–2.53 \0.001
(continued)
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quantification scale. Accordingly, the calculated rela-
tive NPX values are not comparable, as they are calcu-
lated differently for separate analytes. An NPX
measurement allows us to identify changes for individ-
ual protein levels across a unique sample set, thus
allowing the use of data to establish protein signatures.
Statistics
The endpoint for the prognostic evaluation was
disease-specific survival (DSS), defined as the period of
time from surgery until death from disease. We used
the biomarkers as continuous variables in the univari-
ate Cox regression analyses, and the false discovery rate
(FDR) was used for multiple test adjustment.11 For the
Kaplan–Meier analyses, we dichotomized the variables
using the median as the cut-off point. Biomarkers with
p\ 0.1 in univariate Cox regression after FDR adjust-
ment were included in the multivariate forward-
stepping Cox regression (enter criterion p\ 0.05,
removal p. 0.1) with age, gender, and the Dukes stage
as the background variables. Estimates for the time-
dependent receiver operating characteristic (ROC)
curves and area under the curves (AUC) were calcu-
lated using the timeROC package in R.
The linearity of the hazard ratios (HRs) over the
biomarker concentration was examined by transform-
ing the concentration to restricted cubic splines and
analyzing the nonlinearity in R with analysis of var-
iance. Only three biomarkers showed some indication
of nonlinearity (syndecan 1 (SYND1), CD48, and hk8);
we then split these into three categories (cut-off at the
local minimum or maximum) in the multivariate selec-
tion process, while others were used as continuous vari-
ables. Survival time was estimated using the Kaplan–
Meier method according to the biomarker levels. We
used the Mann–Whitney U test to test differences
between groups for continuous variables.
We calculated two-sided p values and considered
p\ 0.05 as statistically significant. Statistical evalua-
tions were completed using IBM’s statistical software
(IBM SPSS Statistics, version 25, International
Table 2. Continued
Biomarker Median (pg/mL) IQR (pg/mL) HR 95% CI p valuea
PODXL 3.16 2.98–3.32 1.06 0.33–3.37 0.979
PPY 5.41 4.38–6.33 1.11 0.91–1.35 0.623
PVRL4 5.77 5.43–6.18 1.49 0.93–2.39 0.347
RET 2.32 1.92–2.70 1.03 0.58–1.81 0.979
RSPO3 2.88 2.52–3.41 1.21 0.89–1.66 0.518
S100A11 2.59 2.35–2.79 1.82 1.18–2.80 0.064
S100A4 2.28 2.05–2.60 1.25 0.68–2.28 0.826
SCAMP3 4.45 3.55–5.31 1.02 0.80–1.30 0.967
SCF 8.43 8.13–8.75 0.61 0.39–0.98 0.202
SEZ6L 4.93 4.67–5.16 0.86 0.41–1.82 0.935
SPARC 5.69 5.57–5.85 0.58 0.12–2.76 0.826
SYND1 6.24 5.78–6.76 1.78 1.21–2.60 0.048
TCL1A 4.65 3.85–5.32 1.07 0.81–1.40 0.935
TFPI-2 7.24 6.85–7.59 1.60 0.90–2.84 0.372
TGF-alpha 1.19 0.95–1.56 2.73 1.41–5.26 0.048
TGFR-2 6.84 6.53–7.21 1.40 0.77–2.54 0.543
TLR3 4.88 4.40–5.34 0.80 0.54–1.19 0.543
TNFRSF19 3.82 3.55–4.30 1.06 0.69–1.63 0.957
TNFRSF4 2.92 2.70–3.50 1.24 0.77–1.97 0.718
TNFRSF6B 4.11 3.54–4.68 1.46 1.05–2.04 0.153
TNFSF13 8.08 7.85–8.49 1.67 0.88–3.15 0.377
TRAIL 7.02 6.76–7.25 0.55 0.24–1.26 0.415
TXLNA 4.50 3.63–5.30 1.04 0.80–1.35 0.957
VEGFA 9.52 9.21–9.90 1.79 1.08–2.97 0.153
VEGFR-2 6.51 6.33–6.69 0.54 0.20–1.45 0.518
VEGFR-3 5.96 5.80–6.10 2.13 0.71–6.40 0.442
VIM 2.52 1.96–3.11 1.62 1.17–2.25 0.048
WFDC2 7.04 6.67–7.42 1.51 0.86–2.67 0.415
WIF-1 5.04 4.76–5.27 1.14 0.58–2.27 0.935
WISP-1 3.95 3.66–4.39 1.51 0.88–2.58 0.410
XPNPEP2 6.53 5.92–6.93 0.88 0.62–1.25 0.826
Bold-faced values have a p value of \0.1. IQR: interquartile range; HR: hazard ratio using a continuous value; 95% CI: 95% confidence interval.
aThe false discovery rate was used for multiple test correction.
bU/mL.
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Out of the 92 biomarkers analyzed, 11 yielded p\ 0.1
in the univariate Cox regression analysis after FDR
correction (Table 2). We also calculated the serum lev-
els as continuous values. Among these, eight biomar-
kers were statistically significant (p\ 0.05). Patients
with low levels of kallikrein 13 (KLK13) and high lev-
els of the following biomarkers had a poor prognosis:
amphiregulin (AREG), carcinoembryonic antigen-
related adhesion molecule 5 (CEACAM5), interleukin
6 (IL6), mucin 16 (MUC-16), SYND1, transforming
growth factor alpha (TGF-alpha) and vimentin (VIM).
Multivariate survival analysis
In the multivariate analysis with the conditional
forward-step Cox regression model, two biomarkers
remained as independent prognostic markers: KLK13
and MUC-16. A multivariable Cox regression model
that included the clinical pathological variables gender,
age over 67, and the Dukes stage served as the baseline
model for 6–48months following primary surgery,
yielding integrated time-dependent AUC at 36months
of 0.763 (95% CI: 0.669–0.856). Retaining the baseline
model variables as the reference with a conditional
forward-step model, only MUC-16 (HR: 2.11; 95%
confidence interval (CI): 1.52–2.92; p\ 0.001) and
KLK13 (HR: 0.37; 95% CI: 0.23–0.60; p\ 0.001)
served as independent prognostic markers, numerically
increasing time-dependent AUC at 36months to 0.860
(95% CI: 0.786–0.934).
MUC-16 association analysis
The MUC-16 levels were significantly lower in patients
with stage A–B disease when comparing patients with
stage C–D disease (Mann–Whitney U test, p=0.037,
Supplementary Table 3). We observed no other asso-
ciations between MUC-16 and clinicopathological
variables.
MUC-16 univariate survival analyses
In the survival analyses, we dichotomized the MUC-16
levels using the median for the Kaplan–Meier survival
analysis and the continuous values in the Cox regression
analysis. Patients with high MUC-16 had a poor prog-
nosis (HR: 1.91; 95% CI: 1.45–2.53; p\ 0.001; Figure 1).
Patients with right-sided disease had a poor prognosis
when the MUC-16 level was high (HR: 2.89; 95% CI:
1.75–4.76; p\ 0.001; Figure 2(a), Table 3). Among
patients with left-sided disease, prognosis was poor for
those with high MUC-16 levels (HR: 1.48; 95% CI: 1.02–
2.15; p=0.041; Figure 2(b), Table 3). Patients with stage
A–B had a poor prognosis when the MUC-16 level was
high (HR: 2.95; 95% CI: 1.46–5.95; p=0.003; Figure
2(c), Table 3). Furthermore, patients with stage C–D had
a poor prognosis with high MUC-16 levels (HR: 1.66;
95% CI: 1.20–2.29; p=0.002; Figure 2(d), Table 3).
Among patients with non-mucinous adenocarcinoma–
Table 3. Univariate hazard ratio for disease-specific survival
for colon cancer patient subgroups according to the MUC-16
levels.a
HR 95% CI p valueb
Gender
Female 1.71 1.12–2.62 0.013
Male 1.96 1.41–2.72 \0.001
Age
<67.8 1.78 1.06–2.98 0.028
.67.8 1.95 1.40–2.72 \0.001
Stage groups
A–B 2.95 1.46–5.95 0.003
C–D 1.66 1.20–2.29 0.002
Side
Right 2.89 1.75–4.76 \0.001





Mucinous 1.32 0.56–3.13 0.522
HR: hazard ratio using the continuous value; 95% CI: 95% confidence
interval.
aMUC-16 dichotomized using the median value.
bp value for the log-rank test.
Figure 1. Disease-specific survival according to the MUC-16
levels based on the log-rank test (Kaplan–Meier).
The cohort was dichotomized according to the median MUC-16 value
(2.92 U/mL).
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type tumors, those with high MUC-16 had a poor prog-
nosis (HR: 2.00; 95% CI: 1.50–2.68; p\ 0.001; Figure
2(e), Table 3), but we found no difference among patients
with mucinous tumors (HR: 1.32; 95% CI: 0.56–3.13;
p=0.522; Figure 2(f), Table 3).
KLK13 association analysis
We observed no associations between KLK13 and clin-
icopathological variables (Mann–Whitney U test;
Supplementary Table 2).
KLK13 univariate survival analyses
In the survival analyses, we dichotomized the KLK13
levels using the median for the Kaplan–Meier survival
analysis and the continuous values used in the Cox
regression analysis. Patients with low levels of KLK13
had a poor prognosis (HR: 0.48; 95% CI: 0.29–0.79;
p=0.004; Figure 3). Table 4 lists the subgroup analy-
ses. Among patients with right-sided disease, low levels
of KLK13 served as a poor prognostic factor (HR:
0.26; 95% CI: 0.12–0.56; p=0.001; Figure 4(a)), but




Figure 2. Disease-specific survival according to MUC-16 subgroup analyses (Kaplan–Meier). The cohort was dichotomized using
the median MUC-16 values. (a) Subgroup analysis for right-sided disease, with the division based on the splenic flexure. (b) Subgroup
analysis for left-sided disease. (c) MUC-16 levels for Dukes stages A–B. (d) MUC-16 levels for Dukes stages C–D. (e) MUC-16 levels
in patients with non-mucinous adenocarcinoma tumors. (f) MUC-16 levels in patients with mucinous tumors. p values reported for
the log-rank test.
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sided disease (HR: 0.77; 95% CI: 0.41–1.43; p=0.404;
Figure 4(b)). Among patients with stage A–B disease,
we found no difference in prognosis based on the
KLK13 levels (HR: 0.50; 95% CI: 0.11–2.24; p=0.498;
Figure 4(c)), whereas patients with stage C–D had a
poor prognosis when the KLK13 level was low (HR:
0.55; 95% CI: 0.34–0.88; p=0.013; Figure 4(d)).
Patients with non-mucinous adenocarcinoma tumors
had a poor prognosis when the KLK13 level was low
(HR: 0.44; 95% CI: 0.25–0.77; p=0.004; Figure 4(e)),
whereas we observed no difference in mucinous tumors
according to the KLK13 level (HR: 0.72; 95% CI:
0.24–2.10; p=0.544; Figure 4(f)).
Discussion
This study aimed to screen for better biomarkers for
CC prognosis using the Proseek Multiplex Oncology II
panel. Using this tool, we studied 92 potential biomar-
kers in 148 CC patients and identified two independent
prognostic biomarkers: MUC-16 and KLK13.
Patients with high levels of MUC-16 and low levels
of KLK13 had a poor prognosis, which we also
observed in subgroups of patients with right-sided dis-
ease and those with an adenocarcinoma histology.
Furthermore, prognosis remained poor in the sub-
groups of patients with low KLK13 levels and right-
sided disease or an adenocarcinoma-type tumor. The
difference in the expressions of MUC-16 and KLK13
between right- and left-sided diseases agrees with
results indicating differences in survival, gene expres-
sion, marker levels, and tumor size.12 Specifically,
right-sided disease obtained a poorer survival, lower
expression of endothelial growth factor receptor
(EGFR), and larger tumors than left-sided disease.12,13
Because the molecular and histological subtypes of
right- and left-sided CRC differ conspicuously, more so
than between rectal cancer and CC, this finding under-
lines this difference even further.13
Mucins are a glycoprotein family constituting a major
component of the mucosal cell lining, thought to serve as
a protective and lubricating barrier against infectious
agents and other particles.14 One member of the mucin
family, MUC-16, is also known as carbohydrate antigen
125 (CA 125), a tumor marker in clinical use in ovarian
cancer patients for follow-up and monitoring.15
Mesothelial cells of the peritoneum, pleura, pericardium,
and endometrium, among others, emit CA 125. When
these epithelia are damaged and change through the peri-
toneal dissemination of CRC, CA 125 levels tend to
rise.16 In the tumorigenesis of adenocarcinomas of the
lung, pancreas, and breast, MUC-16 plays an active role
in cell proliferation and migration, as well as in the inhi-
bition of apoptosis and resistance to cispalatin both in
vivo and in vitro.17 However, in their systematic review,
MUC-16 did not play a role in CRC, contradicting the
findings we report here. This may be partly explained by
the refined PEA method used in this study, which
detected even small changes in marker levels.
In a study among 853 CRC patients with peritoneal
dissemination, those with high levels of serum CA 125 at
the time of diagnosis had a poor prognosis.16 Giessen-
Jung et al.6 studied CA 125 from preoperative serum
samples in 472 CC patients by electrohemiluminescent
immunoenzymometric assays, where CA 125 did not
present any prognostic value. The reason to the differ-
ence in our results could be in different assay analyzation
methods. In serous ovarian cancer diagnosis and follow-
up, high or rising levels of CA 125 indicate pathology,
relapse, or disseminated disease.18 Expression of MUC-
Table 4. Univariate hazard ratio for disease-specific survival
among colon cancer patient subgroups according to the KLK13
levels.a
HR 95% CI p valueb
Gender
Female 0.39 0.18–0.84 0.016
Male 0.58 0.29–1.14 0.112
Age
<67.8 0.79 0.33–1.86 0.583
.67.8 0.35 0.19–0.67 0.001
Stage groups
A–B 0.71 0.16–3.22 0.656
C–D 0.57 0.35–0.93 0.026
Side
Right 0.26 0.12–0.56 0.001
Left 0.77 0.41–1.43 0.404
Histological type
Adenocarcinoma 0.44 0.25–0.77 0.004
Mucinous 0.72 0.24–2.10 0.544
HR: hazard ratio based on the continuous value; 95% CI: 95%
confidence interval.
aKLK13 dichotomized using the median value.
bp value for the log-rank test.
Figure 3. Disease-specific survival according to KLK13 levels
using the log-rank test (Kaplan–Meier).
The cohort was divided according to the median KLK13 value (3.31 pg/mL).
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16 differs also in tumor histology in ovarian cancer.19 We
are not able to conclude if there is a difference in MUC-
16 expression between non-mucinous and mucinous
colon adenocarcinomas, as our mucinous tumor sample
is quite small. Since the results in our multiplex immuno-
panel are relative, the NPX ratios for MUC-16/CA 125
are not directly comparable to the absolute CA 125 val-
ues. Furthermore, since the glycosylation conformation
of MUC-16/CA 125 originating from benign sources or
ovarian cancer cells varies, it remains unknown if the gly-
cosylation conformation change impacts the determina-
tion of MUC-16/CA 125 in CRC.20 Thus, the next step
will consist of validating our results using enzyme-linked
immunosorbent assay (ELISA) for MUC-16 and com-
paring the results with CA 125 determinations from the
same patient cohort.
Kallikreins are hormone-regulated serine proteases
with both tumor-promoting and tumor-suppressive
effects.21,22 KLK3, the most well-established kallikrein,
is known as a prostate-specific antigen (PSA). PSA is
used in prostate cancer follow-up, whereby elevated
levels indicate activation of disease. Talieri et al.23
investigated KLK13 in the cytosolic extract of 122 CC
patients using immunofluorimetry finding that high
levels of KLK13 carried a poor prognosis. However,




Figure 4. Disease-specific survival according to the KLK13 subgroup analyses (Kaplan–Meier). KLK13 was dichotomized using the
median value. (a) KLK13 levels for right-sided disease. (b) KLK13 levels for left-sided disease. (c) KLK13 levels for Dukes stages A–B.
(d) KLK13 levels for Dukes stages C–D. (e) KLK13 levels in patients with non-mucinous adenocarcinoma tumors. (f) KLK13 levels in
patients with mucinous tumors.
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had a good prognosis. Furthermore, our methods dif-
fered, since we analyzed KLK13 levels using PEA
rather than immunofluorimetry. Thus, KLK13 levels
and results may vary.
In oral squamous carcinoma cells, downregulation
of KLK13 facilitates tumor invasiveness and metasta-
sis.24 In 88 malignant esophageal squamous cell carci-
noma tumor patients, those showing a high expression
of KLK13 had a poor prognosis.25 Therefore, the role
of KLK13 differs depending on cancer type, perhaps
due to its central role in the KLK signal cascade,
although its role in carcinogenesis remains unclear.26,27
Previously, White et al.28 proposed using the KLK13
and MUC-16 markers concurrently to detect early stage
ovarian cancer after finding elevated levels of KLK13
and MUC-16/CA 125, as well as elevated KLK13 and
MUC-16 mRNA levels, in immunohistochemistry
staining among 106 ovarian cancer patients. In our
study on CC patients, the KLK13 levels were low and
the MUC-16/CA 125 levels were high in patients with a
poor prognosis. In particular, we note that the MUC-
16 mRNA levels and MUC-16/CA 125 protein levels
are not directly comparable.
One specific advantage of the PEA method is the
small amount of serum needed, as well as the ability to
analyze a large number of biomarkers in a short period
of time. Furthermore, due to its oligonucleotide over-
lapping features, the sensitivity and specificity of PEA
remains superior to conventional PCR.8 However, the
values determined using the PEA multiarray analysis
are relative and, therefore, cannot be directly compared
to the absolute values of different biomarkers or values
obtained from another panel. Chen et al.9 used the
same multiarray PEA method to detect early stage
CRC in a screening setting with good results. Alas,
since we used a different panel of markers, the results
cannot be directly compared.
Furthermore, the ratio between cases and variables
is rather larger, representing a major limitation to this
study. In addition, the Olink panel lacks established
oncological biomarkers, such as CEA and CA19-9.
We included 148 patients in our sample, consisting
solely of CC patients, in order to obtain a more homo-
geneous material. Screening can be carried out on a
small patient cohort, for which PEA represents a
remarkable tool. In order to elaborate upon the role of
MUC-16/CA 125 and KLK13 in clinical practice, fur-
ther validation on a larger sample of patient materials
using specific immunoassays determining absolute con-
centrations are needed.
Conclusion
To conclude, we used PEA as a screening method for
potential prognostic biomarkers in CC. In this
preliminary study, we found that MUC-16/CA 125 and
KLK13 served as independent prognostic markers of
CC, whereby patients with elevated levels of MUC-16
and those with low levels of KLK13 had a poor prog-
nosis. Our results must be validated in larger patient
cohorts and compared with CEA and CA19-9, which
are not included in the panel we used.
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